complia is one of the latest drugs to emerge from the pharmaceutical industry. It's the application of science to solving one of the "Age Old Problems" - how to lose weight. When it comes to suppressing hunger, Acomplia and Phentermine are now up there together as equals, duking it out for leadership of the market.

Acomplia is a branded version of the generic medication rimonabant. Rimonabant is the active ingredient within Acomplia tablets.

What does Acomplia look like?

Strength(s): 20 MG
Imprint: ACOMPLIA 20
Manufacturer: SANOFI AVENTIS

What is the difference between Acomplia and rimonabant?

Rimonabant is the active ingredient in the branded drug Acomplia. Rimonabant is yet to receive approval from the FDA (Food and Drug Administration) for use within the United States.

"Zimulti" is the name Acomplia will be sold under in the US if approval is granted by the FDA.

How does Acomplia work?

Acomplia tablets contain the active ingredient rimonabant, which is a type of medicine called a cannabinoid-1 receptor antagonist. It is used to aid weight loss in people who are obese or overweight. Rimonabant works by blocking receptors called cannabinoid-1 receptors (CB1). These are found in the brain, fat tissue, digestive system, liver and muscles. The CB1 receptors are part of a system in the body called the endocannabinoid system. This system has only recently been discovered and explored. It is involved in regulating energy balance, sugar and fat metabolism and body weight.

What is Acomplia prescribed for?

complia can be prescribed to aid weight loss in obese people who have a body mass index (BMI) of 30kg/m² or more. It can also be prescribed to overweight people with a BMI of 27kg/m² or more who also have additional risk factors for obesity-related diseases, for example type 2 diabetes or unhealthy levels of fats in the blood (dyslipidaemia, eg high triglyceride levels and low HDL-cholesterol levels). It should be used in combination with a reduced calorie diet and exercise program.

Other uses of Acomplia

Acomplia has also found to aid smokers quit smoking.

Who should not take Acomplia?

  • Severely decreased liver function.
  • Severely decreased kidney function.
  • Uncontrolled serious psychiatric illness.
  • Major depressive illness
  • People taking antidepressant medicines.
  • Pregnancy.
  • Breastfeeding.
  • Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption (Acomplia tablets contain lactose).

This medicine is not recommended for children and adolescents under 18 years of age, because its safety and efficacy have not been studied in this age group.

This medicine should not be used if you are allergic to one or any of its ingredients. Please inform your doctor or pharmacist if you have previously experienced such an allergy.

If you feel you have experienced an allergic reaction, stop using this medicine and inform your doctor or pharmacist immediately.

Possible side effects of Acomplia

Nausea Vomiting Diarrhoea
Dry mouth Anorexia Depressions
Anxiety Irritability Nervousness
Sleep disorders Impaired memory Impaired attention

Recommended Acomplia dosage

Recommended dosage is one 20mg tablet daily.

Acomplia Overdose

Experience with Acomplia overdosage is limited. In cases of overdose the following symptoms were reported; headache, euphoria, fatigue and insomnia. If an Acomplia overdose is suspected ensure that airways are kept clear, monitor heart activity and contact a doctor immediately.

Acomplia Ingredients:

Active Ingredient: Rimonabant

Inactive Ingredients: Tablet core: maize starch, lactose monohydrate, povidone K 30 (E1201), croscarmellose sodium (E468), sodium laurilsulfate (E487), microcrystalline cellulose (E460), magnesium stearate
Tablet coating: lactose monohydrate, hypromellose 15 mPa.s (E464), titanium dioxide (E171), macrogol 3000
Tablet polishing: carnauba wax (E903)

Who makes Acomplia?

Acomplia is a branded version of the generic drug Rimonabant. Rimonabant was developed and is manufactured by French pharmaceutical company, Sanofi-Aventis.

By the end of 2007 Rimonabant had received market authorization by 40 countries.

Following the decision by the FDAs advisory council not to recommend the approval of Rimonabant within the United States, Sanofi-Aventis withdrew their drug application in June 2007. Sanofi-Aventis propose to submit a revised drug application at some point in the future seeking approval to market the drug as Zimulti in the US.